增强子
生物
基因
CTCF公司
癌基因
发起人
遗传学
基因表达
细胞周期
作者
Sunniyat Rahman,Gianna Bloye,Nadine Farah,Jonas Demeulemeester,Joana R. Costa,David O’Connor,Rachael Pocock,Tanya Rapoz-D’Silva,Adam Turňa,Ling-Yi Wang,Soo Wah Lee,Adele K. Fielding,Juliette Roels,Roman Jaksik,Małgorzata Dawidowska,Pieter Van Vlierberghe,Suzana Hadjur,Jim R. Hughes,James O. J. Davies,Alejandro Gutiérrez
出处
期刊:Blood
[Elsevier BV]
日期:2024-09-24
被引量:2
标识
DOI:10.1182/blood.2024024300
摘要
Oncogenes can be activated in cis through multiple mechanisms including enhancer hijacking events and noncoding mutations that create enhancers or promoters de novo. These paradigms have helped parse somatic variation of noncoding cancer genomes, thereby providing a rationale to identify noncanonical mechanisms of gene activation. Here we describe a novel mechanism of oncogene activation whereby focal copy number loss of an intronic element within the FTO gene leads to aberrant expression of IRX3, an oncogene in T cell acute lymphoblastic leukemia (T-ALL). Loss of this CTCF bound element downstream to IRX3 (+224 kb) leads to enhancer hijack of an upstream developmentally active super-enhancer of the CRNDE long noncoding RNA (-644 kb). Unexpectedly, the CRNDE super-enhancer interacts with the IRX3 promoter with no transcriptional output until it is untethered from the FTO intronic site. We propose that 'promoter tethering' of oncogenes to inert regions of the genome is a previously unappreciated biological mechanism preventing tumorigenesis.
科研通智能强力驱动
Strongly Powered by AbleSci AI